

Early submission

Chronic heart failure in adults: diagnosis and management

Review questions

NICE guideline tbc

Review questions

June 2025

Early submission

Disclaimer

The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or service users. The recommendations in this guideline are not mandatory and the guideline does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or their carer or guardian.

Local commissioners and/or providers have a responsibility to enable the guideline to be applied when individual health professionals and their patients or service users wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with compliance with those duties.

NICE guidelines cover health and care in England. Decisions on how they apply in other UK countries are made by ministers in the [Welsh Government](#), [Scottish Government](#), and [Northern Ireland Executive](#). All NICE guidance is subject to regular review and may be updated or withdrawn.

Copyright

© NICE 2025. All rights reserved. Subject to [Notice of Rights](#).

ISBN:

Contents

| | |
|------------------------|---|
| Review questions | 5 |
|------------------------|---|

Review questions

| Review questions | |
|------------------|---|
| 1.1 | What is the most clinical and cost-effective pharmacological treatment approach (using beta-blockers, ACE inhibitors/angiotensin-receptor blockers/angiotensin receptor neprilysin inhibitor, mineralocorticoid receptor antagonists and sodium-glucose cotransporter-2 inhibitors) in adults with chronic heart failure with reduced left ventricular ejection fraction? |
| 1.2 | What is the most clinical and cost-effective pharmacological treatment approach (using beta-blockers, ACE inhibitors/angiotensin-receptor blockers/angiotensin receptor neprilysin inhibitor and mineralocorticoid receptor antagonists) in adults with chronic heart failure with mildly reduced left ventricular ejection fraction? |
| 1.3 | What is the clinical and cost effectiveness of intravenous iron in adults with chronic heart failure and iron deficiency? |